We encourage authors to provide detailed information within their submission to facilitate the interpretation and replication of experiments. Authors can upload supporting documentation to indicate the use of appropriate reporting guidelines for health-related
Sample-size estimation
 You should state whether an appropriate sample size was computed when the study was being designed  You should state the statistical method of sample size computation and any required assumptions  If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use
Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:
Replicates  You should report how often each experiment was performed  You should include a definition of biological versus technical replication  The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates  If you encountered any outliers, you should describe how these were handled  Criteria for exclusion/inclusion of data should be clearly stated  High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)
We used a sample size of 10 participants for the in vivo study. This is typical for controlled circadian/diurnal laboratory studies of human volunteers. We have previously employed n = 8 participants in a control group undergoing a similar laboratory protocol and meeting the same inclusion/exclusion criteria, to detect 24h rhythmicity of clock genes in subcutaneous adipose tissue biopsies (1). Given that the rhythms are often most robust for clock gene expression, and may vary between tissues, we included at least the same number of participants in this study of the entire transcriptome in skeletal muscle. In total this resulted in 60 samples to be analysed for the in vivo study.
For the in vitro analysis we went for a high time-resolution (2h) over two full cycles (48h) but reduced the number of donors to 2. This resulted in 100 samples to be analysed (50 samples per donor due to siCTRL and siClock condition). Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:
(For large datasets, or papers with a very large number of statistical tests, you may upload a single table file with tests, Ns, etc., with reference to sections in the manuscript.)
Group allocation  Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied  Indicate if masking was used during group allocation, data collection and/or data analysis Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:
Additional data files ("source data")  We encourage you to upload relevant additional data files, such as numerical data that are represented as a graph in a figure, or as a summary table  Where provided, these should be in the most useful format, and they can be uploaded as "Source data" files linked to a main figure or table  Include model definition files including the full list of parameters used  Include code used for data analysis (e.g., R, MatLab)
The differential gene expression analysis was performed with the R package edgeR (2) . First, transcripts expressing lower than 3 counts per million (CPM) and non-informative transcripts (e.g., non-aligned) were filtered. To minimize the log-fold changes between the samples for most genes, a set of scaling factors for the library sizes were estimated with the trimmed mean of M-values (TMM) method (3). The dispersion was estimated with the quantile-adjusted conditional maximum likelihood (qCML) method. Once the dispersion estimates were obtained, we performed the testing procedures for determining differential expression using the exact test (4). A false discovery rate (FDR) of < 0.05 was used to select differentially expressed genes.
N/A for the in vivo work, as all participants were grouped together.
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 Avoid stating that data files are "available upon request"
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The rhythmic analysis was performed with the R software. Various reformatting functions were developed; raw data were transformed to log2 reads per kilobase per million mapped reads (RPKM) as described previously (5) . Only transcripts with log2 RPKM>0 for each of the fourth conditions (2 subjects, siControl or siCLOCK) were kept, avoiding big variability for weakly expressed transcripts. The 48 time points of each condition were used to define a local regression function (loess function in R). This step allows smoothing the curve and reducing local variability. The function was then used to calculate 10 different measures (maximum and minimum slopes, first and second extremum, minimum-maximum ratio, autocorrelation, measure of scattering, residues on the loess function, residues on a linear function and period). These features were used to classify gene expression patterns in 4 different groups: rhythmic genes (category "circadian"), genes that show only one pic at the beginning of the time course (category "one peak"), linearly (category "linear") and scattered expressed genes (category "cloud"). The R package randomForest was used to classify genes. The function attributes a probability to each transcript per condition. To be classified in one category, this probability must be the highest value and superior to 0.5 in at least one category. If no probabilities were superior to 0.5 for the four categories, transcripts were grouped into model 16 (non-rhythmic). The 11 major circadian genes, including ARNTL (BMAL1), NR1D1 (REVERBα), NR1D2 (REVERBβ), PER1, PER2, PER3, CRY1, CRY2, NPAS2, TEF and BHLHE41, were selected to train the random forest model. The same number of genes was also integrated in the training dataset for the 3 other groups. This dataset was then passed to the random forests training algorithm and gene conditions that were assigned to one of these categories with a high score (0.9) were integrated in the training dataset. This procedure was repeated until 500 curves per group were identified.
